Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.

Lorenza LandiRita ChiariMarcello TiseoFederica D'IncàClaudio DazziAntonio ChellaAngelo DelmonteLaura BonannoDiana GiannarelliDiego Luigi CortinovisFilippo de MarinisGloria BorraAlessandro MorabitoCesare GridelliDomenico GalettaFausto BarbieriFrancesco GrossiEnrica CapellettoGabriele MinutiFrancesca MazzoniClaudio Verusio Emilio BriaGreta AlìRossella BrunoAgnese ProiettiGabriella FontaniniLucio CrinòFederico Cappuzzo

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Crizotinib induces response in a fraction of MET-deregulated NSCLC. Additional studies and innovative therapies are urgently needed.

Keyphrases

phase ii
advanced non small cell lung cancer
clinical trial
tyrosine kinase
open label
epidermal growth factor receptor
double blind
phase iii
small cell lung cancer
placebo controlled
cell death
dna damage
reactive oxygen species
cross sectional
oxidative stress
brain metastases